FSGS, MPGN, and TMA (among others) are finally recognized as a pattern of injury as opposed to a specific disease. For TMA this figure says it all

You can still sign up!!

Instructions for Presenters Now Available Are you speaking, chairing a session, or presenting a poster at IIGANN 2025 Symposium? Find all instructions here: iigann2025.com/instructions-f… #iigann2025 #iigann #Nephropathy #IgANephropathy

Dont miss this session Well worked up scenario #ECNeph Arvind Canchi (Conjeevaram)🇮🇳 Augusto Cesar S Santos Jr Dr. Oriba Dan Langoya

#ASNC2025 has partnered with the #ISPD1 to organize the first-ever home dialysis course! An educational opportunity not to missed - registration link : asn-online.org/education/kidn…

KDIGO is excited to share the publication of the 2025 Clinical Practice Guideline for the Management of IgA Nephropathy (#IgAN) and IgA Vasculitis (#IgAV), along with the Executive Summary in Kidney International. Read the Guideline in KI: kdigo.co/KDIGO-IgAN-IgA… Download the Executive

كل عام ووطننا في عزٍّ وأمان، دامت بلادي عزيزة شامخة 💚🇸🇦

📢 This month Int. Soc. of Peritoneal Dialysis North America Ch. Journal Club is discussing: 📷 October Topic: Association of Sex With All-Cause and Cause-Specific Peritoneal Dialysis Discontinuation Register and join in your respective time zone: ispd.org/NAC/jcs/

It is so cool seeing images of Rich standing on stage and presenting this It was only 15 years ago I sat in his clinic and we had little more than RAASi and fish oil for pts with IgA Nephropathy Now an explosion of therapies precisely targeting the mechanisms disease #KidneyWk

Happy birthday Hiddo Heerspink & congrats on the FINE-ONE late-breaker!! This is HUGE for our patients with T1DM & CKD who, as you aptly said, are unable to take advantage of therapies approved for T2DM with CKD. Thank you for leading by example & constantly striving to get new

A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy | New England Journal of Medicine nejm.org/doi/full/10.10… NEJM American Society of Nephrology #kidneyweek25

Starting off with IgA Nephropathy at Plenary Session! ▶️ 1. The impact of new tools by Vlado Perkovic - first #ASN2025 publication Kidney International! 🔥 ▶️ 2. Just published NEJM - Dr. Richard Lafayette on the ORIGIN 3 trial: Atacicept led to remarkable results! 🤯 #GlomerularDisease

Next up SGLT2i in different CKD populations (diabetic status and proteinuria) This is a meta-analysis

#NephJC is covering Kidney Week daily, spotlighting late-breaking and high-impact clinical science for nephrologists who want the key data fast. #KidneyWk ✍️Day 1 covered by Cristina Popa 🦋 and Swapnil Hiremath @hswapnil.medsky.social nephjc.com/news/kidneywk2…

SMART-C simultaneous publication in JAMA! Bottom line: Absolute benefits of SGLT2i far exceed any potential harms in people with & without diabetes, and UACR < & >200mg Time to accelerate implementation to improve population health: jamanetwork.com/journals/jama/… #kidneywk

B-cell depleting strategies in lupus nephritis 🐺 ▶️ Obinutuzumab confers higher complete remission rates vs other mAbs ▶️ Immunological reset 🆕 CAR-T cells - deeper depletion in varied differentiation stages (for refractory cases!) #KidneyWk #ISGDtweets #GlomerularDisease

Truly ‚full house’ excellent session about hot lupus nephritis topics chaired by Sayna Norouzi, MD, FASN and Juan M. Mejia-Vilet, starting from a fantastic talk of Andreas Kronbichler about 25’ treatment goals #KidneyWk

Not because of believe but based on the strong evidence - flozinate! #kidneywk